Phase 1a single-ascending dose trial of Ent001 in healthy volunteers
Latest Information Update: 29 Jan 2024
At a glance
- Drugs ENT-001 (Primary)
- Indications Inflammatory bowel diseases; Type 1 diabetes mellitus
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Enthera
- 23 Jan 2024 Results presented in an Enthera Media Release.
- 23 Jan 2024 Status changed to completed, according to an Enthera media release.
- 07 Mar 2023 Planned number of patients changed to 30.